Actemra: Liver Injury, Heart Problems, Pancreatitis
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
These medical conditions may have been identified as possible Actemra side effects:
- Drug-Induced Liver Injury (DILI)
- Liver Failure / Hepatic Failure
- Drug-Induced Hepatitis
- Heart Failure
- Heart Attacks / Myocardial Infarction (MI)
- Strokes (CVA)
- Interstitial Lung Disease (ILD)
Actemra (tocilizumab) is approved by the FDA for the treatment of several different medical conditions:
- Moderately to severely active rheumatoid arthritis in adult patients who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs);
- Giant Cell Arteritis (GCA) in adult patients;
- Polyarticular Juvenile Idiopathic Arthritis (PJIA) in patients 2 years of age and older; and,
- Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older.
The responsible drug company is Genentech, Inc.
We are currently investigating cases of these Actemra side effects as possible drug injury lawsuits against this drug company — and not your doctor.
Free Actemra Case Evaluation
We encourage you to submit a Drug Injury Law Case Review – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
Most Recent Article About This Drug
Actemra Liver Injury Risks Warnings Added To Drug Label In June 2019
The FDA sent an email on June 13, 2019 about Drug Safety-related Labeling Changes (SrLC) which alerted us to a revised version of the Actemra Prescribing Information document used in the US. Upon review of this new section added to the “Warnings and Precautions” part of the June 2019 Actemra drug label (accessed 6/13/19):
To read more of this article, click below:
Serious cases of hepatic injury have been observed in patients taking intravenous or subcutaneous ACTEMRA. Some of these cases have resulted in liver transplant or death. Time to onset for cases ranged from months to years after treatment initiation with [Actemra (tocilizumab)]. While most cases presented with marked elevations of transaminases (> 5 times ULN), some cases presented with signs or symptoms of liver dysfunction and only mildly elevated transaminases….
Here are a few earlier Actemra articles we posted on Drug Injury Watch:
- Risk Of Actemra Associated Liver Injury Being Assessed By Health Canada, With Drug Label Change Likely To Follow (May 2019)
- Actemra Side Effects: Pulmonary Hypertension, Interstitial Lung Disease, Pulmonary Alveolar Proteinosis (August 2018)
- Despite The High Number Of Actemra – Pancreatitis Cases Reported To FDA, No Warning Added To Drug Label (June 2017)
We are currently investigating cases of these Actemra side effects as possible drug injury lawsuits against Genentech, Inc., the responsible drug company.[Read article in full at original source]
Earlier articles by attorney Tom Lamb on the Side Effects Blog:
- Actemra Drug-Induced Liver Injuries Warning From Health Canada
- Actemra: FDA Evaluating Regulatory Action Due To Signs Of Serious Risk
- No Warning Added By FDA To Drug Label For Actemra About Pancreatitis
Free Case Evaluation: Actemra >>
All content by attorney Tom Lamb